Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 14/20 | 0.56 |
| ▸ | SELP | P16109 | 4/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316002 | 0.97 | TLR4 (0.56) | TLR4SELPSSTR4SSTR1SSTR2 | |
| SCHEMBL2306676 | 0.97 | TLR4 (0.56) | TLR4SELPSSTR4SSTR1SSTR2 | |
| SCHEMBL2306681 | 0.97 | TLR4 (0.56) | TLR4SELPSSTR4SSTR1SSTR2 | |
| SCHEMBL2315995 | 0.97 | TLR4 (0.56) | TLR4SELPSSTR4SSTR1SSTR2 | |
| SCHEMBL7714520 | 0.93 | TLR4 (0.60) | TLR4SELP | |
| SCHEMBL2311952 | 0.92 | TLR4 (0.49) | TLR4SELP | |
| SCHEMBL2311946 | 0.92 | TLR4 (0.49) | TLR4SELP | |
| SCHEMBL2306694 | 0.92 | TLR4 (0.52) | TLR4SELPSSTR4SSTR1SSTR2 | |
| SCHEMBL2306688 | 0.92 | TLR4 (0.52) | TLR4SELPSSTR4SSTR1SSTR2 | |
| SCHEMBL18789816 | 0.91 | TLR4 (0.57) | TLR4SELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112924-A1 | SYNTHETIC DERIVATIVES OF MPL AND USES THEREOF | K2 HEALTHVENTURES LLC, AS CANADIAN COLLATERAL AGENT | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112924-A1 | SYNTHETIC DERIVATIVES OF MPL AND USES THEREOF | MPL, CD47, PLTP | TLR4 544/4885SELP 86/4885SSTR4 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.